Ombitasvir
As of the edition of 20 October 2026, Ombitasvir is a small molecule: marketed, first approved in 2015 (US); US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Technivie
- First approved
- 24 July 2015 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- AbbVie
- Withdrawn from market
- 25 September 2024 (in some regions)
- Registered trials
- 48, 3 stopped early
- Disease areas
- Digestive system; Infections; Urinary and reproductive; Pregnancy and women's health; Immune system
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 8 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 12 | 10 | 0 | 1 |
| Phase 3 | 21 | 19 | 0 | 2 |
| Phase 4 | 5 | 3 | 0 | 0 |
| All trials | 48 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant and Lead sponsor of trials | 2011 to now |